Loading...

Sarepta Therapeutics, Inc.

0L35.L•LSE
Healthcare
Medical - Pharmaceuticals
£18.30
£-1.05(-5.41%)

Sarepta Therapeutics, Inc. (0L35.L) Stock Overview

Explore Sarepta Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 73.3/100

Key Financials

Market Cap1.9B
P/E Ratio-7.54
EPS (TTM)$-4.29
ROE-0.20%
Fundamental Analysis

AI Price Forecasts

1 Week$38.20
1 Month$87.91
3 Months$51.51
1 Year Target$124.16

0L35.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Sarepta Therapeutics, Inc. (0L35.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 30.03, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $124.16.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -7.54 and a market capitalization of 1.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

30.03RSI (14)
-4.86MACD
40.15ADX
Revenue Growth
52.97%
↑ 52.97%
Profit Growth
£-2.55
↑ 143.89%
EPS Growth
£-2.55
↑ 142.59%
Operating Margin
-5.25%
↑ 181.43%
ROE
-20.00%
↑ 143.89%
Dividend Yield
0.00%
Analyst Recommendations data is not available for 0L35.LAnalyst Recommendations details for 0L35.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

CEO

Douglas S. Ingram

Employees

1,372

Headquarters

215 First Street, Cambridge, MA

Founded

2018

Frequently Asked Questions

;